• Home
  • Services
    • DMPK/ADME
    • Ocular PD/Efficacy
    • Bioanalytical
    • Biochemistry
    • In-Life Capabilities
  • About
    • About Us
    • Publications
    • News
  • Careers
  • Contact
PharmOptima MENU

News

  • Press Release

    Genesis Biotechnology Group Acquires BioBlocks to Grow the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development (GD3)

    10/2021
  • Press Release

    Genesis Drug Discovery & Development Appoints Anthony Rohr as Chief Operating Officer

    9/2021
  • Press Release

    Genesis Drug Discovery & Development Appoints Laura Sailor Veteran CRO Business Development Leader as Director of Business Development

    9/2021
  • Press Release

    Genesis Drug Discovery and Development acquires Integrated Analytical Solutions to add "off the shelf" PK profiling capabilities to its portfolio.

    3/2021
  • Press Release

    Genesis Drug Discovery and Development expands its presence in the clinical space by acquiring STATKING Clinical Services

    1/2021
  • Press Release

    Genesis Biotechnology Group announces second year of CRO relationship with Yale University

    12/2020
  • Press Release

    Genesis Biotechnology Group acquires Comparative Biosciences, Inc. (CBI) to add GLP Toxicology and Safety Pharmacology to its portfolio of Preclinical Services

    8/2020
  • Press Release

    Genesis Drug Discovery & Development (GD3) Announces Appointment of Anthony Rohr, as Chief Executive Officer of PharmOptima.

    8/2020
  • Press Release

    Genesis Biotechnology Group acquires NEDP to grow the Preclinical Chemistry services portfolio of Genesis Drug Discovery & Development

    11/2019
  • Press Release

    Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio by Acquiring NexusPharma.

    6/2019
  • Press Release

    Genesis Drug Discovery & Development Announces Operating Agreement with Ophthy-DS, Inc.

    2/2019
  • Press Release

    Genesis Biotechnology Group announces partnership with Yale University

    10/2018
  • Press Release

    Genesis Biotechnology Group Expands Preclinical Contract Research Portfolio by Acquiring PharmOptima

    3/2017

News & Events

  • 10/2021
    Image

    Genesis Biotechnology Group Acquires BioBlocks to Grow the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development (GD3)

    Learn More
  • 9/2021
    Image

    Genesis Drug Discovery & Development Appoints Anthony Rohr as Chief Operating Officer

    Learn More
  • 9/2021
    Image

    Genesis Drug Discovery & Development Appoints Laura Sailor Veteran CRO Business Development Leader as Director of Business Development

    Learn More
  • 3/2021
    Image

    Genesis Drug Discovery and Development acquires Integrated Analytical Solutions to add "off the shelf" PK profiling capabilities to its portfolio.

    Learn More
  • 1/2021
    Image

    Genesis Drug Discovery and Development expands its presence in the clinical space by acquiring STATKING Clinical Services

    Learn More
  • 12/2020
    Image

    Genesis Biotechnology Group announces second year of CRO relationship with Yale University

    Learn More
  • 8/2020
    Image

    Genesis Biotechnology Group acquires Comparative Biosciences, Inc. (CBI) to add GLP Toxicology and Safety Pharmacology to its portfolio of Preclinical Services

    Learn More
  • 8/2020
    Image

    Genesis Drug Discovery & Development (GD3) Announces Appointment of Anthony Rohr, as Chief Executive Officer of PharmOptima.

    Learn More
  • 11/2019
    Image

    Genesis Biotechnology Group acquires NEDP to grow the Preclinical Chemistry services portfolio of Genesis Drug Discovery & Development

    Learn More
  • 6/2019
    Image

    Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio by Acquiring NexusPharma.

    Learn More
  • 2/2019
    Image

    Genesis Drug Discovery & Development Announces Operating Agreement with Ophthy-DS, Inc.

    Learn More
  • 10/2018
    Image

    Genesis Biotechnology Group announces partnership with Yale University

    Learn More
  • 3/2017
    Image

    Genesis Biotechnology Group Expands Preclinical Contract Research Portfolio by Acquiring PharmOptima

    Learn More
  • Careers
  • Terms of Use
  • Privacy Policy

©2022 PharmOptima LLC All Rights Reserved.

GD3
A Member of the Genesis Biotechnology Group